Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FAYZ A HUDEFI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Addiction Medicine

NPI
1992740393
CMS profile
135740
Location
FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$124.97

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $124.97 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $124.97 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FAYZ A HUDEFI

NPI 1992740393 · CMS profile ID 135740

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Addiction Medicine

FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
FAYZ A HUDEFI, NPI 1992740393, CMS profile ID 135740, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992740393?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $124.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $124.9711/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184963715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $346.37 4
PY2020 $203.40 6
PY2021 $241.28 6
PY2023 $34.77 2
PY2024 $1,099.97 3
PY2025 $124.97 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,184,915.74 413
PY2024 Principal investigator $2,303,282.98 204
PY2023 Principal investigator $6,541,371.44 120
PY2022 Principal investigator $34,086.76 8
PY2021 Principal investigator $312,565.61 85
PY2020 Recipient $1,312.46 7
PY2020 Principal investigator $543,799.24 155
PY2019 Recipient $2,502.81 13
PY2019 Principal investigator $1,252,649.46 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $165.00 12/31/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670118209
Principal investigator 1 Allergan Inc. $165.00 12/31/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670118989
Principal investigator 1 Allergan Inc. $266.96 12/31/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119373
Principal investigator 1 Allergan Inc. $2,450.24 12/31/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670119788
Principal investigator 1 Allergan Inc. $500.00 12/31/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670119978
Principal investigator 1 Corcept Therapeutics $5,000.00 12/04/2019 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 695141209
Principal investigator 1 Corcept Therapeutics $1,000.00 12/04/2019 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 695141215
Principal investigator 1 Corcept Therapeutics $800.00 12/04/2019 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 695141225
Principal investigator 1 Corcept Therapeutics $5,200.00 12/04/2019 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 695141231
Principal investigator 1 Corcept Therapeutics $1,500.00 12/04/2019 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 695141236
Principal investigator 1 Corcept Therapeutics $3,000.00 12/04/2019 Non-covered Recipient Entity
Pillar Clinical Research, LLC
CORT118335-876 No dispute reported 06/30/2026 695141241
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,669.85 11/27/2019 Non-covered Recipient Entity
PROSCIENCERESEARCHGROUP LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 No dispute reported 06/30/2026 696055155
Principal investigator 1 Alkermes, Inc. $85.00 10/31/2019 Non-covered Recipient Entity
WOODLAND INTERNATIONAL RESEARCH GROUP
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526157
Principal investigator 1 Alkermes, Inc. $85.00 10/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526167
Principal investigator 1 Boehringer Ingelheim International GmbH $48.16 10/28/2019 Non-covered Recipient Entity
WOODLAND RSRCH NORTHWEST, LLC
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703924877
Recipient Corcept Therapeutics $287.00 10/22/2019 Covered Recipient Physician Study 876 No dispute reported 06/30/2026 695141289
Recipient Corcept Therapeutics $155.46 10/22/2019 Covered Recipient Physician Study 876 No dispute reported 06/30/2026 695141294
Recipient Corcept Therapeutics $152.42 10/22/2019 Covered Recipient Physician Study 876 No dispute reported 06/30/2026 695141298
Principal investigator 1 LEO Pharma AS $5,469.00 10/22/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686859665
Principal investigator 1 Alkermes, Inc. $68.91 10/16/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526165
Principal investigator 1 TOLMAR, INC. $2,953.00 10/15/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
TOL3010B No dispute reported 06/30/2026 638019611
Recipient Corcept Therapeutics $87.68 10/14/2019 Covered Recipient Physician Study 876 No dispute reported 06/30/2026 695141281
Recipient Corcept Therapeutics $49.26 10/14/2019 Covered Recipient Physician Study 876 No dispute reported 06/30/2026 695141285
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $3,147.75 10/10/2019 Non-covered Recipient Entity
PSYCHIATRIC CARE & RESEARCH CENTER
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696055017
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $128.75 10/04/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050037
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 10/04/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050039
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $50.00 10/04/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050043
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $201.71 10/04/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050047
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $678.90 10/03/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050025
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $128.75 10/03/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050029
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $124.99 10/03/2019 Covered Recipient Physician A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 696050033
Principal investigator 1 Biogen, Inc. $13,454.00 10/01/2019 Non-covered Recipient Entity
Pillar Clinical Research
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) No dispute reported 06/30/2026 675311123
Principal investigator 2 LEO Pharma AS $924.00 10/01/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686859038
Principal investigator 1 TOLMAR, INC. $4,465.80 09/04/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
TOL3010B No dispute reported 06/30/2026 638019607
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/01/2019 Non-covered Recipient Entity
WOODLAND RSRCH NORTHWEST, LLC
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703921919
Principal investigator 1 Alkermes, Inc. $85.00 08/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526211
Recipient Corcept Therapeutics $407.89 08/30/2019 Covered Recipient Physician Study 876 No dispute reported 06/30/2026 695141275
Principal investigator 1 Eisai Inc. $300.30 08/22/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY DBA ST LOUIS CLINICAL TRIALS
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder No dispute reported 06/30/2026 702547909
Principal investigator 1 Alkermes, Inc. $124.24 08/16/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526229
Principal investigator 2 LEO Pharma AS $1,350.00 08/13/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686857651
Principal investigator 1 Allergan Inc. $5,643.30 08/06/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670063585
Principal investigator 2 LEO Pharma AS $1,990.00 08/06/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686857239
Principal investigator 1 Allergan Inc. $19,999.40 08/01/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670062159
Principal investigator 1 Alkermes, Inc. $85.00 07/31/2019 Non-covered Recipient Entity
WOODLAND INTERNATIONAL RESEARCH GROUP
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526155
Principal investigator 1 Alkermes, Inc. $85.00 07/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526189
Principal investigator 1 Alkermes, Inc. $85.00 07/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526191
Principal investigator 1 Alkermes, Inc. $85.00 07/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526207
Principal investigator 1 Alkermes, Inc. $85.00 07/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526209
Principal investigator 1 Allergan Inc. $29,400.00 07/30/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670061661
Principal investigator 1 Allergan Inc. $73,146.20 07/09/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670055227
Principal investigator 1 Alkermes, Inc. $147.15 07/08/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526205
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $17,220.64 07/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 No dispute reported 06/30/2026 696054649
Principal investigator 1 Alkermes, Inc. $85.00 06/30/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526187
Principal investigator 1 Alkermes, Inc. $651.90 06/04/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526185
Principal investigator 1 Genentech, Inc. $175.00 06/04/2019 Non-covered Recipient Entity
ERG HOLDING CO LLC
PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD No dispute reported 06/30/2026 681082101
Principal investigator 1 Alkermes, Inc. $4,072.80 06/03/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526227
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $8,486.85 05/27/2019 Non-covered Recipient Entity
PROSCIENCERESEARCHGROUP LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696054487
Principal investigator 1 Alkermes, Inc. $35.00 05/25/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526183
Principal investigator 1 Alkermes, Inc. $150.00 05/24/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526225
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $8,000.00 05/20/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696054423
Principal investigator 1 Alkermes, Inc. $100.00 05/17/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526223
Principal investigator 1 Allergan Inc. $14,574.90 05/16/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670046147
Principal investigator 1 Genentech, Inc. $1,700.00 05/15/2019 Non-covered Recipient Entity
ERG HOLDING CO LLC
PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD No dispute reported 06/30/2026 681083021
Principal investigator 1 Allergan Inc. $18,146.90 05/14/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670044627
Principal investigator 1 Alkermes, Inc. $1,546.80 05/07/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526221
Principal investigator 1 Alkermes, Inc. $1,853.70 05/06/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526181
Principal investigator 1 Alkermes, Inc. $35.00 05/03/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526179
Principal investigator 1 Genentech, Inc. $215.00 04/29/2019 Non-covered Recipient Entity
ERG HOLDING CO LLC
PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD No dispute reported 06/30/2026 681081593
Principal investigator 1 Neurocrine Biosciences, Inc. $221.00 04/25/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565835
Principal investigator 1 Alkermes, Inc. $48.13 04/19/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526243
Principal investigator 1 Genentech, Inc. $1,804.00 04/18/2019 Non-covered Recipient Entity
ERG HOLDING CO LLC
PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD No dispute reported 06/30/2026 681079841
Principal investigator 1 Alkermes, Inc. $45.94 04/16/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526163
Principal investigator 1 Alkermes, Inc. $46.59 04/16/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526219
Principal investigator 1 Alkermes, Inc. $27.76 04/15/2019 Non-covered Recipient Entity
Woodland Research
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526159
Principal investigator 1 Alkermes, Inc. $20.00 04/15/2019 Non-covered Recipient Entity
Woodland Research
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526161
Principal investigator 1 Merck Sharp & Dohme Corporation $5,731.47 04/12/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Risperidone as Active Control in Subjects Experiencing an AcuteEpisode of Schizophrenia. No dispute reported 06/30/2026 691316165
Principal investigator 1 Allergan Inc. $16,492.50 04/11/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670037235
Principal investigator 1 LEO Pharma AS $10,131.00 04/11/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686854039
Principal investigator 1 LEO Pharma AS $162.00 04/11/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686854045
Principal investigator 1 Alkermes, Inc. $1,000.00 04/10/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526241
Principal investigator 1 Allergan Inc. $4,204.70 04/09/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670036645
Principal investigator 1 Allergan Inc. $25,718.40 04/09/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670036691
Principal investigator 1 Alkermes, Inc. $70.00 04/06/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526177
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $3,397.00 04/05/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 696053947
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 04/04/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565473
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 04/04/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565549
Principal investigator 1 Alkermes, Inc. $228.00 03/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526239
Principal investigator 1 Neurocrine Biosciences, Inc. $743.00 03/21/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565259
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $37.90 03/20/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006503
Principal investigator 1 Eisai Inc. $6,593.40 03/19/2019 Non-covered Recipient Entity
CLINICAL PHARMACOLOGY OF MIAMI, INC.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702547907
Principal investigator 1 Genentech, Inc. $6,012.00 03/18/2019 Non-covered Recipient Entity
ERG HOLDING CO LLC
PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD No dispute reported 06/30/2026 681086297
Principal investigator 1 Allergan Inc. $3,106.50 03/14/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670030621
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $59.80 03/13/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006501
Principal investigator 1 Allergan Inc. $1,264.45 03/12/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670029931
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $29,385.19 03/06/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 696053485
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $29,700.00 03/06/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006493
Principal investigator 1 Allergan Inc. $5,000.00 03/05/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670029005
Principal investigator 1 Alkermes, Inc. $85.00 02/28/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526175
Principal investigator 1 Alkermes, Inc. $85.00 02/28/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526203
Principal investigator 1 Alkermes, Inc. $85.00 02/22/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526193
Principal investigator 1 Allergan Inc. $16,340.00 02/21/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670026115
Principal investigator 1 Allergan Inc. $4,750.00 02/19/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670025787
Principal investigator 1 Allergan Inc. $5,750.00 02/19/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670025911
Principal investigator 1 Alkermes, Inc. $45.94 02/15/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526199
Principal investigator 1 Alkermes, Inc. $54.55 02/15/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526201
Principal investigator 1 Alkermes, Inc. $155.30 02/15/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526215
Principal investigator 1 Alkermes, Inc. $750.27 02/15/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526217
Principal investigator 1 LEO Pharma AS $6,936.00 02/12/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST LLC
TRALOKINUMAB DRUG INTERACTION TRAIL No dispute reported 06/30/2026 686851939
Principal investigator 1 TOLMAR, INC. $19,471.50 02/08/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
TOL3010B No dispute reported 06/30/2026 638019599
Principal investigator 1 Alkermes, Inc. $1,937.25 02/06/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526237
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $52,448.40 02/06/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006489
Principal investigator 1 Allergan Inc. $8,025.60 02/05/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670021305
Principal investigator 1 Allergan Inc. $1,900.00 02/05/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670021673
Principal investigator 1 Allergan Inc. $8,738.10 02/05/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670021758
Principal investigator 1 Alkermes, Inc. $85.00 01/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526173
Principal investigator 1 Alkermes, Inc. $85.00 01/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526195
Principal investigator 1 Alkermes, Inc. $85.00 01/31/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 653526197
Principal investigator 1 Neurocrine Biosciences, Inc. $27.56 01/31/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564231
Principal investigator 1 Allergan Inc. $47,850.00 01/29/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670020523
Principal investigator 1 Allergan Inc. $3,125.00 01/29/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670020819
Principal investigator 1 Alkermes, Inc. $105.00 01/25/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526171
Principal investigator 1 TOLMAR, INC. $1,239.30 01/22/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
TOL3010B No dispute reported 06/30/2026 638019597
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $92,793.79 01/19/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696053167
Principal investigator 1 Alkermes, Inc. $50.00 01/17/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 No dispute reported 06/30/2026 653526213
Principal investigator 1 Allergan Inc. $7,505.00 01/17/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670017711
Principal investigator 1 Alkermes, Inc. $7,331.63 01/16/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526233
Principal investigator 1 Alkermes, Inc. $2,850.00 01/16/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526235
Principal investigator 1 Allergan Inc. $18,200.00 01/15/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670016749
Principal investigator 1 Allergan Inc. $400.00 01/15/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670016863
Principal investigator 1 Allergan Inc. $2,000.00 01/15/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670017027
Principal investigator 1 Alkermes, Inc. $12,825.00 01/10/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia No dispute reported 06/30/2026 653526231
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 01/10/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563805
Principal investigator 1 Neurocrine Biosciences, Inc. $338.00 01/10/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563811
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $379,810.39 01/10/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
PROTOCOL 331-201-00080 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696052951
Principal investigator 1 Allergan Inc. $5,890.00 01/08/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670015333
Principal investigator 1 Allergan Inc. $48,315.10 01/08/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670015413
Principal investigator 1 TOLMAR, INC. $2,112.00 01/07/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
TOL3010B No dispute reported 06/30/2026 638019585
Principal investigator 1 TOLMAR, INC. $332.00 01/07/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
TOL3010B No dispute reported 06/30/2026 638019589
Principal investigator 1 Alkermes, Inc. $140.00 01/04/2019 Non-covered Recipient Entity
WOODLAND RESEARCH NORTHWEST, LLC.
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia No dispute reported 06/30/2026 653526169
Principal investigator 1 Allergan Inc. $8,400.00 01/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 670013821
Principal investigator 1 Allergan Inc. $2,675.20 01/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC ST LOUIS CLINICAL TRIAL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 670014109
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 01/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562619
Principal investigator 1 Neurocrine Biosciences, Inc. $64.00 01/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562621
Principal investigator 1 Neurocrine Biosciences, Inc. $128.00 01/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562647
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $61,943.50 01/03/2019 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006483